February 19, 2020

Trends in Extrapelvic Deep Endometriosis

Incidence may be higher than previously believed

Dr.Kho_650x450

Extrapelvic deep endometriosis may be more common than previously believed, according to the results of a recent systematic review of the literature.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Without comparative studies, we don’t have recommendations about how best to diagnose and treat extrapelvic endometriosis. Clinical suspicion tends to be low, and in general, physicians may not know what to look for,” states Rosanne M. Kho, MD, a gynecologist with the Cleveland Clinic’s Ob/Gyn & Women’s Health Institute and associate editor of the Journal of Minimally Invasive Gynecology. “As a result, the diagnosis and management of extrapelvic endometriosis at distant sites can be quite challenging.”

Endometriosis is thought to develop as part of retrograde menstruation, when endometriotic cells reach the abdominopelvic region via the fallopian tube, undergo neoangiogenesis and implant at potentially distant sites. The condition is labeled deep endometriosis if these endometriotic nodules are more than 5 mm in size.

“Primary extrapelvic endometriosis can affect nearly every organ system in the body. We once thought it was rare, but our review indicates that the incidence may be higher than originally believed,” Dr. Kho notes.

In the review, researchers identified more than 5,000 articles related to extrapelvic endometriosis. After excluding duplicates, review articles and those involving the bowel, cancer or scar endometriosis, 179 were included in the final analysis. For the purposes of this review, data was organized by site of extrapelvic endometriosis.

Advertisement

Abdominal endometriosis

Abdominal endometriosis was separated into two categories: parietal endometriosis (PE), which included primary lesions in the abdominal wall, groin and perineum; and visceral endometriosis (VE), which included lesions in the abdominal organs.

For PE, the mean age at clinical presentation was 38.5 years (range, 25-73). Common presenting symptoms were a palpable mass, parietal pain and umbilical bleeding. Diagnosis generally involved ultrasound, magnetic resonance imaging or computed tomography. Surgery — generally wide local excision — was performed in 97% of the PE cases. General surgeons performed 71.1% of these procedures, with only 15.7% performed by a gynecologist. Adjuvant hormonal treatment was rarely reported.

For VE, the mean age at presentation was 40.3 years (range, 25-73). Patients with liver endometriosis presented with upper abdominal pain and abdominal mass; patients with kidney endometriosis reported flank pain, hematuria and pyelonephritis; patients with pancreatic endometriosis reported epigastric pain; and patients with liver endometriosis presented with acute liver failure and upper abdominal pain. CT was commonly used in the diagnosis of VE, and most patients were treated with surgery. All patients reported symptom improvement.

Thoracic endometriosis

Lesions involving the diaphragm, pleura and lung were grouped as thoracic endometriosis (TE). At clinical presentation, the mean age of patients was 22.6 (range, 16-54). The most common symptom was pneumothorax. Lesions were generally found through chest X-ray or CT, and confirmed by histologic or immunohistochemical analysis. In most cases, lesions associated with TE were removed surgically, and adjuvant hormonal therapy was reported in only 15.5% of cases.

Advertisement

Endometriosis in other sites

Other, rarer sites of endometriosis were grouped together, and included lesions involving the vascular, lymphatic and central nervous systems, the brain, skeletal muscles and peripheral nerves. Common presenting symptoms included paresthesia and cyclic pain with radiation according to topographic site involvement, and dysmenorrhea. At clinical presentation, patients ranged in age from 21 to 58 years. MRI was used for preoperative evaluation, showing a hyperintense T1 or isointense T2 lesion. Surgical excision with adjuvant hormonal therapy was used in many cases; however, one patient with brain endometriosis was treated with gonadotropin-releasing hormone agonist (GnRHa) and bilateral salpingo-oophorectomy, and one patient with nasal endometriosis was treated with GnRHa alone.

Extrapelvic endometriosis — not so rare after all

“Extrapelvic endometriosis may not be as rare as we originally thought, and clinical presentation varies widely,” Dr. Kho says. “With limited evidence, we can’t determine the best treatment choice for each type and extent of extrapelvic endometriosis. Detailed case reporting and validated patient assessment tools — perhaps through a worldwide patient registry — would go a long way toward developing consistent standards of care for patients with this debilitating condition.”

Related Articles

Paternalism in women's health
July 12, 2023
Commentary: Paternalism in Ob/Gyn Practice

How we create obstacles for sexual, reproductive and menopausal healthcare despite our best intentions

hot flashes
June 12, 2023
A New Family of NK3 Receptor Antagonists Offer Menopausal Symptom Relief

One approved non-hormonal therapy and another on the horizon reduce vasomotor symptoms

Hormone therapy for menopause
June 14, 2022
Hormone Therapy for Prevention Requires a Nuanced Approach

Some post-menopausal patients may benefit from treatment

Linda Bradley, MD
May 11, 2022
Race and Ethnicity Affects Care for Patients with Endometriosis

Study shows higher rates of complications, laparotomies among non-white women

Vaginitis diagnosis
December 17, 2021
The Art and Science of Diagnosing Vaginitis

Proper diagnosis and treatment require a careful mix of patient and clinical considerations

Uterine-preserving surgery
August 30, 2021
Hysteropexy or Hysterectomy for Prolapse Repair: Which Is Safer?

Study uniquely powered to compare adverse effects

Woman placing transdermal testosterone patch on thigh
April 6, 2021
The Role of Androgen Therapy in Female Sexual Health

What is female hypoactive sexual desire disorder and how is it treated?

Woman dispensing hormone replacement gel
April 2, 2021
Prescribing Testosterone and DHEA: The Role of Androgens in Women

Indications and best-practice recommendations for the use of androgen therapy

Ad